A5055431631- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Chronic Myeloid Leukemia Treatments
- Drug Transport and Resistance Mechanisms
- Multiple Myeloma Research and Treatments
- Cell Adhesion Molecules Research
- Histone Deacetylase Inhibitors Research
- Cytomegalovirus and herpesvirus research
- Blood disorders and treatments
- Protein Degradation and Inhibitors
- Immunodeficiency and Autoimmune Disorders
- Myasthenia Gravis and Thymoma
- Vascular Tumors and Angiosarcomas
- Hereditary Neurological Disorders
- Protein Tyrosine Phosphatases
- Immune cells in cancer
- Celiac Disease Research and Management
- Renal Transplantation Outcomes and Treatments
- Cancer Genomics and Diagnostics
- Neutropenia and Cancer Infections
- Immunotherapy and Immune Responses
- Inflammasome and immune disorders
Geneva College
2025
Lille’s Cardiology Hospital
2020-2024
University of Geneva
2024
University Hospital of Geneva
2024
Centre Hospitalier Universitaire de Lille
2014-2023
CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers
2020-2023
Université de Lille
2017-2023
Onco Lille
2023
Inserm
2017-2023
Centre National de la Recherche Scientifique
2020-2023
<title>Abstract</title> <italic>CBFA2T3::GLIS2</italic> fusion positive pediatric acute myeloid leukemia (AML) remains one of the worst prognostic AML subgroups. To uncover innovative targeted therapeutic approaches in this disease subtype we performed genome-scale CRISPR-Cas9 screening that highlighted a strong, selective dependency on <italic>JAK2</italic> compared to other types cancer. Using doxycycline-inducible knockout (KO) system, validated cell lines, observing impaired...
ABCB1 is a member of the ATP binding cassette transporter family and high activity considered as poor prognostic factor in acute myeloid leukemia (AML) treated with intensive chemotherapy, its direct relation drug resistance remains unclear. We evaluated clinical parameters treatment response to standard chemotherapy 321 patients de novo AML. assessed multiple relationships activity—ex vivo resistance, gene expression, inhibitor quinine were evaluated. was observed 58% AML linked low white...
CD81 is a cell surface protein which belongs to the tetraspanin family. While in multiple myeloma its expression on plasma cells associated with worse prognosis, this has not yet been explored acute myeloid leukemia (AML). We measured membrane of AML at diagnosis, evaluated association characteristics and influence patient outcome after intensive chemotherapy cohort 134 patients. was detected 92/134 (69%) Patients expressing had elevated leukocyte count (P=0.02) were more likely classified...
ABSTRACT Background Acyclovir treatment is an efficient prophylaxis to prevent varicella‐zoster virus (VZV) reactivation after allogeneic hematopoietic stem cell transplantation (HSCT). Aims This single center retrospective study tried determine if the lymphocytes immunophenotyping could help duration of prophylaxis, and evaluated complications, associated risk factors for VZV infection. Methods Results Eighty‐four children underwent HSCT, in which 77 received acyclovir prophylaxis....
Germline mutations in runt-related transcription factor 1 (RUNX1), ETS variant 6 (ETV6) and ankyrin repeat domain 26 (ANKRD26) have been recognised as responsible of autosomal dominant inherited thrombocytopenia or platelet disorder, with an increased risk developing haematological malignancies (HM), mainly acute leukaemia (AL) myelodysplastic syndrome (MDS) (Duployez et al., 2016). Importantly, while all these disorders are associated abnormalities count functions, may be mild a bleeding...
Acute myeloid leukemia (AML) is a heterogeneous, and if not treated, fatal disease.It the most common cause of leukemia-associated mortality in adults.Initially, AML disease hematopoietic stem cells (HSC) characterized by arrest differentiation, subsequent accumulation blast cells, reduced production functional elements.Heterogeneity extends to presence (LSC), with this dynamic cell compartment evolving overcome various selection pressures imposed upon during progression treatment.To further...
Abstract Background There are currently few data on the outcome of acute myeloid leukemia (AML) in adolescents after allogeneic HSCT. The aim this study is to describe and its specific risk factors for children, young adults a first HSCT AML. Methods In retrospective study, we compared AML patients receiving between 2005 2017 according their age at transplantation’s time: children (< 15 years, n = 564), adolescent post-adolescent (APA) (15–25 647) (26–40 years; 1434). Results With median...
Acute myeloid leukemia (AML) is a heterogeneous, and if not treated, fatal disease. It the most common cause of leukemia-associated mortality in adults. Initially, AML disease hematopoietic stem cells (HSC) characterized by arrest differentiation, subsequent accumulation blast cells, reduced production functional elements. Heterogeneity extends to presence (LSC), with this dynamic cell compartment evolving overcome various selection pressures imposed upon during progression treatment. To...
Abstract Antithymocyte globulin is a major drug in transplantation. rATG has been successfully used to prevent graft‐versus‐host disease allogeneic HSCT. However, its first infusion associated with reactions ranging from simple fevers distributive shocks and may interfere the transplant conditioning. To evaluate impact of rate on clinical tolerability, we conducted retrospective study all pediatric HSCT patients who received (Thymoglobulin®) as part their conditioning at Lille University...
Abstract Background: There are currently few data on the outcome of acute myeloid leukemia (AML) in adolescents and young adults (AYAs) after allogeneic HSCT. The aim this study is to describe its specific risk factors for children, AYAs a first HSCT AML. Methods : In retrospective study, we compared AML patients receiving between 2005 2017 according their age at transplantation’s time: children (<15 years, n=564), (15-25 n=647) (26-40 years; n= 1434). Results: With median follow-up 4.37...